VivoSeq
Oncology

HCC - Hepatocellular Carcinoma

5

Pipeline Programs↗

3

Active Trials↗

5

Companies Involved↗

HCC - Hepatocellular Carcinoma is an early-stage landscape with 5 programs across 5 companies. The most active players are ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Xiang-Qian, Bristol-Myers Squibb. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

1 program

Phase 2X

Xiang-Qian

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2Roche logo

Roche

1 program

Phase 2Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

3

clinical trials

Not yet recruiting3 · 100%

Clinical Trials

Trial Activity

Shuganhuazhuo Formula (Chinese Herbal Medicine) in the Combined Treatment of Advanced Hepatocellular Carcinoma With Damp-Heat and Blood Stasis Syndrome: An Open-Label Randomized Controlled Trial
Not yet recruiting·XXiang-Qian·Phase 2·NCT07691645·120 enrolled
Phase II Clinical Study of IMM2510 for Injection Combined With IMM27M for Injection in Advanced Hepatocellular Carcinoma
Not yet recruiting·IImmuneOnco Biopharmaceuticals (Shanghai) Inc.·Phase 2·NCT07687914·50 enrolled
A Prospective, Single-Arm, Single-Center Exploratory Clinical Study of Stereotactic Body Radiation Therapy Combined With QL1706 in the Second-Line Treatment of Hepatocellular Carcinoma
Not yet recruiting·HHebei Medical University Fourth Hospital·Approved·NCT07668570·36 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)